Form 4: Sage Therapeutics COO Disposes Shares Following Supernus Merger Completion

Sage Therapeutics' Chief Operating Officer, Christopher Benecchi, disposed of all his common stock, restricted stock units, and stock options as a result of the company's merger with Supernus Pharmaceuticals, Inc. becoming effective.

Summary

• Christopher Benecchi, Chief Operating Officer of Sage Therapeutics, Inc., disposed of all his beneficial ownership in Sage Therapeutics common stock, restricted stock units (RSUs), and stock options.
• The disposition occurred on July 31, 2025, which was the effective date of the merger between Sage Therapeutics, Inc. and Supernus Pharmaceuticals, Inc. (via its subsidiary Saphire, Inc.).
• Under the merger agreement, each outstanding Sage Therapeutics common share was cancelled and converted into the right to receive $8.50 per share in cash (the 'Closing Amount') plus one contingent value right (CVR).
• Each CVR represents the right to receive up to an additional $3.50 per share in cash upon the satisfaction of specified milestones.
• Restricted Stock Units (RSUs) held by Mr. Benecchi were fully vested, cancelled, and converted into a cash payment equal to the Closing Amount multiplied by the number of shares subject to the RSU, plus one CVR per RSU.
• Stock options with an exercise price less than the Closing Amount were fully vested, cancelled, and converted into a cash payment equal to the excess of the Closing Amount over the exercise price, multiplied by the number of shares subject to the option, plus one CVR per option share.
• Stock options with an exercise price greater than or equal to the Closing Amount were cancelled with no consideration.
• Mr. Benecchi disposed of 28,053 shares of common stock, 36,375 shares underlying RSUs, 12,500 stock options with an exercise price of $6.05, and 40,000 stock options with an exercise price of $6.97.

Sentiment

Score: 8

Explanation: The sentiment is positive as the filing confirms the successful completion of a merger, providing shareholders with immediate cash and potential future upside via CVRs. The disposition of securities is a direct, expected consequence of this value-realizing event.

Positives

• The merger completion provides immediate liquidity to shareholders, including the reporting person, through a cash payment of $8.50 per share.
• Shareholders also receive Contingent Value Rights (CVRs) which offer potential additional cash payments of up to $3.50 per share based on future milestone achievements.
• All outstanding restricted stock units and in-the-money stock options were fully vested and converted into cash and CVRs, providing a clear payout for equity compensation.

Negatives

• The disposition of shares means the reporting person no longer holds direct equity in Sage Therapeutics, as the company has been acquired.
• Stock options with an exercise price equal to or greater than the $8.50 Closing Amount were cancelled without any consideration, resulting in a loss of potential value for those specific options.

Risks

• The value of the Contingent Value Rights (CVRs) is contingent upon the satisfaction of specified milestones, meaning the full $3.50 per share is not guaranteed and depends on future events.

Future Outlook

The filing indicates that the Contingent Value Rights (CVRs) represent a right to receive up to $3.50 per share in cash upon the satisfaction of specified future milestones, as described in a previously filed Form 8-K.

Industry Context

This filing reflects the completion of a significant M&A transaction in the biotechnology sector, where a larger pharmaceutical company, Supernus Pharmaceuticals, acquired Sage Therapeutics. Such acquisitions are common strategies for larger firms to expand their pipeline or market presence, and for smaller biotech firms to realize value for their shareholders and potentially accelerate drug development with greater resources.

Comparison to Industry Standards

• The acquisition structure, involving an upfront cash payment combined with Contingent Value Rights (CVRs), is a common mechanism in biotech M&A. This structure allows the acquirer (Supernus) to mitigate risk by tying a portion of the payout to the successful achievement of specific clinical or regulatory milestones, while providing selling shareholders (Sage) with potential upside beyond the initial cash consideration.
• Comparable transactions in the biotech space often feature similar CVR structures, particularly when the acquired company's value is heavily dependent on the future success of pipeline assets. For example, the acquisition of MyoKardia by Bristol Myers Squibb included CVRs tied to FDA approval of mavacamten, and the acquisition of Acceleron Pharma by Merck also included CVRs related to a specific drug candidate.

Stakeholder Impact

• Shareholders of Sage Therapeutics received cash consideration and CVRs for their shares, realizing value from their investment.
• The reporting person, as a key executive, had his equity compensation converted into cash and CVRs, aligning his interests with the merger's outcome.

Next Steps

• Monitoring the satisfaction of specified milestones for the Contingent Value Rights (CVRs) to determine if additional cash payments of up to $3.50 per share will be realized.

Key Dates

Keywords

Sage Therapeutics, Supernus Pharmaceuticals, Merger, Acquisition, Form 4, SEC Filing, Beneficial Ownership, Contingent Value Rights, CVR, Stock Options, Restricted Stock Units, Equity Compensation, Biotechnology, Pharmaceuticals